Bevacizumab Combined with Pemetrexed for Advanced Non-Squamous Non-Small Cell Lung Cancer
the Cancer Therapy Advisor take:
After being combined with standard first-line chemotherapy, bevacizumab (a monoclonal antibody against vascular endothelial growth factor) was shown to have clinical benefit for patients with advanced non-squamous non-small cell lung cancer.
Research recently published in Tumour Biology: The Journal of The International Society for Oncodevelopmental Biology and Medicine investigated the affect of combining bevacizumab with pemetrexed as it related to progression-free survival in patients with advanced non-squamous non-small cell lung cancer after the failure of a minimum of one prior chemotherapy treatment.
In order to be eligible for inclusion in the study, patients must have failed at least one prior platinum-based chemotherapy treatment, have metastatic, locally advanced, or recurrent non-squamous non-small cell lung cancer, and performance status of 0 to 2.
Patient in the study received 500 mg/m2 of intravenous pemetrexed on day 1 and folic acid, vitamin B12, dexamethasone, and 7.5 mg/kg of intravenous bevacizumab on day 1 of a 21-day cycle.
Treatment was administered until toxicity was unacceptable, disease progression occurred, or the treatment was stopped by request of the patient. The primary endpoint of the study was progression-free survival. Thirty-three patients were enrolled between December 2011 and October 2013.
The median age of enrolled patients was 55 years and 63.6% of patients were women. Median overall survival was 15.83 months (95 % confidence interval: 10.52, 21.15 months) and overall response rates were 6.45%.
Overall, the research showed that combining bevacizumab and pemetrexed on a 21-day cycle is effective for improving the progression-free survival of patients with non-squamous non-small cell lung cancer who have failed prior therapies.
Bevacizumab was shown to have clinical benefit for patients with advanced non-squamous non-small cell lung cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed